Meritking Giriş: Meritking Spor BahisleriMarsbahis Giriş: Marsbahis Para Yatırma Ve Çekme İşlemleriMavibet Giriş: Mavibet Güvenilir Mi, Mavibet Bonus Ve KampanyalarMeritking Giriş: Meritking Güvenilir Mi, Meritking Bonus Ve KampanyalarMarsbahis Giriş: Marsbahis Giriş Adresi, Marsbahis Mobilden Giriş 2026Mavibet Giriş: Mavibet Spor Bahisleri, Mavibet Casino Ve Slot OyunlarıMeritking Giriş: Meritking Spor BahisleriMarsbahis Giriş: Marsbahis Para Yatırma Ve Çekme İşlemleriMavibet Giriş: Mavibet Güvenilir Mi, Mavibet Bonus Ve KampanyalarMeritking Giriş: Meritking Giriş Adresi, Meritking Casino Ve Slot OyunlarıMarsbahis Giriş: Marsbahis Güvenilir Mi, Marsbahis Spor BahisleriMavibet Giriş: Mavibet Para Yatırma Ve Çekme İşlemleriMeritking Giriş: Meritking Spor BahisleriMarsbahis Giriş: Marsbahis Para Yatırma Ve Çekme İşlemleriMavibet Giriş: Mavibet Güvenilir Mi, Mavibet Mobilden Giriş 2026Meritking Giriş: Meritking Para Yatırma Ve Çekme İşlemleriMarsbahis Giriş: Marsbahis Spor BahisleriMavibet Giriş: Mavibet Giriş Adresi, Mavibet Güvenilir MiMeritking Giriş: Meritking Giriş Adresi, Meritking Casino Ve Slot OyunlarıMarsbahis Giriş: Marsbahis Güvenilir Mi, Marsbahis Spor BahisleriMavibet Giriş: Mavibet Para Yatırma Ve Çekme İşlemleriMeritking Giriş: Meritking Spor Bahisleri, Meritking Casino Ve Slot OyunlarıMarsbahis Giriş: Marsbahis Para Yatırma Ve Çekme İşlemleriMavibet Giriş: Mavibet Güvenilir Mi, Mavibet Bonus Ve KampanyalarMeritking Giriş: Meritking Canlı Destek Ve İletişimMarsbahis Giriş: Marsbahis Casino Ve Slot OyunlarıMavibet Giriş: Mavibet Bonus Ve KampanyalarMeritking Giriş: Meritking Spor Bahisleri, Meritking Giriş AdresiMarsbahis Giriş: Marsbahis Para Yatırma Ve Çekme İşlemleriMavibet Giriş: Mavibet Güvenilir MiMeritking Giriş: Meritking Canlı Destek Ve İletişimMarsbahis Giriş: Marsbahis Casino Ve Slot Oyunları, Marsbahis Spor BahisleriMavibet Giriş: Mavibet Bonus Ve Kampanyalar, Mavibet Giriş AdresiMeritking Giriş: Meritking Güvenilir Mi, Meritking Bonus Ve KampanyalarMarsbahis Giriş: Marsbahis Giriş Adresi, Marsbahis Mobilden Giriş 2026Mavibet Giriş: Mavibet Spor BahisleriMeritking Giriş: Meritking Giriş Adresi, Meritking Mobilden Giriş 2026Marsbahis Giriş: Marsbahis Güvenilir Mi, Marsbahis Bonus Ve KampanyalarMavibet Giriş: Mavibet Para Yatırma Ve Çekme İşlemleriMeritking Giriş: Meritking Para Yatırma Ve Çekme İşlemleriMarsbahis Giriş: Marsbahis Spor Bahisleri, Marsbahis Casino Ve Slot OyunlarıMavibet Giriş: Mavibet Giriş Adresi, Mavibet Mobilden Giriş 2026Meritking Giriş: Meritking Canlı Destek Ve İletişimMarsbahis Giriş: Marsbahis Casino Ve Slot OyunlarıMavibet Giriş: Mavibet Bonus Ve KampanyalarMeritking Giriş: Meritking Giriş AdresiMarsbahis Giriş: Marsbahis Güvenilir MiMavibet Giriş: Mavibet Para Yatırma Ve Çekme İşlemleriMeritking Giriş: Meritking Güvenilir Mi, Meritking Giriş AdresiMarsbahis Giriş: Marsbahis Giriş Adresi, Marsbahis Bonus Ve KampanyalarMavibet Giriş: Mavibet Spor Bahisleri, Mavibet Casino Ve Slot OyunlarıMeritking Giriş: Meritking Spor Bahisleri, Meritking Casino Ve Slot OyunlarıMarsbahis Giriş: Marsbahis Para Yatırma Ve Çekme İşlemleriMavibet Giriş: Mavibet Güvenilir Mi, Mavibet Bonus Ve KampanyalarMeritking Giriş: Meritking Spor Bahisleri, Meritking Casino Ve Slot OyunlarıMarsbahis Giriş: Marsbahis Para Yatırma Ve Çekme İşlemleriMavibet Giriş: Mavibet Güvenilir Mi, Mavibet Bonus Ve KampanyalarMeritking Giriş: Meritking Güvenilir Mi, Meritking Bonus Ve KampanyalarMarsbahis Giriş: Marsbahis Giriş Adresi, Marsbahis Mobilden Giriş 2026Mavibet Giriş: Mavibet Spor BahislerikalitebetextrabetMeritking Giriş: Meritking Spor Bahisleri, Meritking Casino Ve Slot OyunlarıMarsbahis Giriş: Marsbahis Para Yatırma Ve Çekme İşlemleriMavibet Giriş: Mavibet Güvenilir Mi, Mavibet Bonus Ve KampanyalarAntalya EscortBursa Escort Bayanistanbul çilingirAntalya Escort BayanHasta YatağıAntalya Escort bayanAntalya Escort BayanMeritking Giriş: Meritking Güvenilir Mi, Meritking Bonus Ve KampanyalarMarsbahis Giriş: Marsbahis Giriş Adresi, Marsbahis Mobilden Giriş 2026Mavibet Giriş: Mavibet Spor Bahisleri, Mavibet Casino Ve Slot OyunlarıBursa Escort BayanEdirne Escort Bayanİzmir Escort BayanBursa Escort BayanAntalya Escort Bayanbetroy girişbetroy girişAntalya Masaj spa Sauna adresi buradabetroyhacklinkhacklink satın alhacklink albacklinkbacklink albacklink satın alhacklink kaufenhacklink buyкупить хак-ссылкиشراء روابط مخترقةcomprar enlaces de spam购买外链हैकलिंक खरीदेंacheter des liens de référencementহ্যাকলিংক কিনুনcomprar links de spambeli hacklinkbursa escortbetroy güncel girişforzabet girişforzabet girişcratosroyalbetsuperbetinholiganbetjojobetkavbetJojobet GirişJojobetJojobetcratosroyalbetdedebetgrandpashabetgrandpashabet girişbetwoonbetwoon girişcratosroyalbetcratosroyalbet girişradissonbetradissonbet girişdedebetdedebet girişmaxwinmaxwin girişmaxwinmaxwin girişsuperbetsuperbet girişRamadabetramadabet girişdamabetdamabet girişbetwildbetwild girişgrandpashabetgrandpashabet girişgrandpashabet güncel girişgrandpashabetgrandpashbet girişhttps://x.com/HASiL_Malaysiahttps://x.com/HASiL_Malaysia girişhttps://x.com/HASiL_Malaysiagrandpashabetgrandpashabet güncel girişgrandpashabet girişgrandpashabet deneme bonusudeneme bonusudeneme bonusu veren sitelergrandpashabetgrandpashabet girişgrandpashabet güncel adresi

Antibiotic for IBD could offer targeted treatment for Crohn’s disease

Researchers at McMaster University and the Massachusetts Institute of Technology (MIT), led by McMaster assistant professor Jon Stokes, have identified a new antibiotic that could offer a more targeted approach to treating inflammatory bowel disease (IBD), including Crohn’s disease.

Named enterololin, the antibiotic selectively attacks a family of bacteria associated with intestinal infections while sparing beneficial gut bacteria. Its discovery could help address a limitation of existing antibiotics, which can disrupt the gut microbiome and create opportunities for drug-resistant bacteria to thrive.

In a further breakthrough, Stokes and his collaborators used artificial intelligence (AI) to predict how the antibiotic works, with subsequent laboratory experiments confirming the model’s findings. The approach reduced the time required for mechanism-of-action research from up to two years to just six months, demonstrating how AI could accelerate the development of new treatments.

A more targeted antibiotic for IBD

Most antibiotics currently used in clinical settings have broad-spectrum activity, meaning they target harmful bacteria but can also destroy beneficial microorganisms living in the gut.

This disruption can leave the intestinal environment vulnerable to colonisation by invasive and drug-resistant bacteria, including Escherichia coli (E. coli). These organisms can contribute to the worsening of conditions such as Crohn’s disease.

Enterololin offers a different approach. Developed at McMaster, the antibiotic has a narrow spectrum of activity, targeting Enterobacteriaceae, a family of bacteria that includes E. coli, rather than affecting the wider gut microbiome.

By selectively eliminating these bacteria, the drug could also reduce opportunities for antibiotic-resistant strains to establish themselves in the intestines.

The discovery represents a potential new direction for developing an antibiotic for IBD, although further research and clinical testing will be needed before its suitability for patients can be established.

AI predicts how the antibiotic works

Alongside identifying enterololin, the researchers demonstrated a new application for AI in pharmaceutical development.

AI has increasingly been used to screen chemical compounds and identify molecules with potential therapeutic properties. However, establishing precisely how a promising drug candidate works has remained a significant challenge.

Known as mechanism-of-action (MOA) research, this process is essential for understanding how a drug interacts with its target. It also helps researchers assess safety, determine appropriate dosages, improve effectiveness and identify potential new treatment targets.

Traditional MOA investigations can take up to two years and cost approximately $2m.

To accelerate the process, Stokes contacted colleagues at MIT’s Computer Science and Artificial Intelligence Laboratory to explore whether emerging machine learning platforms could help with the investigation.

Using DiffDock, an AI model developed by MIT professor Regina Barzilay, the researchers received a prediction about enterololin’s mechanism of action in just 100 seconds.

The model suggested that the antibiotic targeted LolCDE, a microscopic protein complex essential to the survival of certain bacteria.

Laboratory experiments confirm AI prediction

The prediction provided researchers with a starting point for investigating the drug, but experimental validation remained necessary.

Led in large part by McMaster PhD candidate Denise Catacutan, the team conducted conventional laboratory investigations to establish whether enterololin acted through the predicted pathway.

The experiments confirmed that the AI model had correctly identified its target.

By using the prediction to guide their investigations, researchers completed the MOA work in six months, cutting approximately 18 months from the conventional development timeline. The cost was also reduced from around $2m to $60,000.

The findings demonstrate how AI could help address one of the more time-consuming and expensive stages of drug development, moving beyond identifying potential drug candidates to explaining how they function.

Enterololin moves towards human trials

The next stage will focus on preparing the antibiotic for potential clinical use.

Stokes’ spin-out company, Stoked Bio, has licensed enterololin from McMaster University and is working to optimise the drug for human use.

The company is also investigating modified versions of the antibiotic against other drug-resistant bacteria, including Klebsiella, with early results described as promising.

Researchers hope enterololin could be ready to enter human trials within three years.

For people living with Crohn’s disease and other forms of IBD, the research offers a promising avenue for investigating treatments that target problematic bacteria without unnecessarily disrupting the wider gut microbiome.

Team Health Accessible
Author

Team Health Accessible

Health & Wellness Editorial Team

HealthAccessible editorial team delivers trusted, accessible, and evidence-based health information for everyone.

Leave a Reply

Your email address will not be published. Required fields are marked *

Share